Usefulness of 11C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions

2015 ◽  
Vol 126 (3) ◽  
pp. 577-583 ◽  
Author(s):  
Atsushi Watanabe ◽  
Yoshihiro Muragaki ◽  
Takashi Maruyama ◽  
Jun Shinoda ◽  
Yoshikazu Okada
Keyword(s):  
Decision Making ◽  
Positron Emission Tomography ◽  
Treatment Decision ◽  
Brain Lesions ◽  
Emission Tomography ◽  
Treatment Decision Making ◽  
Positron Emission

Impact of F-18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography on Oncologic Patient Management: First 2 Years' Experience at a Single Canadian Cancer Center

2010 ◽  
Vol 61 (1) ◽  
pp. 13-18 ◽  
Author(s):  
Daniel F. Worsley ◽  
Don C. Wilson ◽  
John E. Powe ◽  
Francois Benard
Keyword(s):  
Computed Tomography ◽  
Decision Making ◽  
Positron Emission Tomography ◽  
Patient Management ◽  
Treatment Decision ◽  
Emission Tomography ◽  
Cancer Center ◽  
Positron Emission ◽  
Pet Ct ◽  
Oncology Center

Purpose The purpose of this study was to assess the influence of positron emission tomography–computed tomography (PET-CT) results on patient management from a single Canadian oncology center during its first 2 years of operation. Methods A total of 3,779 consecutive patients, 18 years of age and older, who were referred for PET-CT imaging at the British Columbia Cancer Agency between July 1, 2005 and June 30, 2007, were included in this analysis. Results were tabulated from a standard questionnaire, which was given to referring physicians following completion of their patient's PET-CT study. Results From July 1, 2005 to June 30, 2007, 3,779 consecutive fluoro-2-deoxyglucose PET-CT examinations were performed in patients aged 18 years or older. A total of 3,429 referring-physician surveys (90.7%) were returned. The results of the PET-CT study resulted in a change in treatment decision in 49.8% of the studies and resulted in improved decision making in 83.2% of the studies. Conclusion This series demonstrated that the results from PET-CT studies performed at a single Canadian oncology center during the first 2 years of its operation altered patient management in 50% of cases and resulted in improved decision making in the majority of cases.

Positron Emission Tomography and Computed Tomography in Differential Diagnosis between Recurrent or Residual Glioma and Treatment-Induced Brain Lesions

1989 ◽  
Vol 30 (2) ◽  
pp. 121-128 ◽  
Author(s):  
A. Lilja ◽  
H. Lundqvist ◽  
Y. Olsson ◽  
B. Spännare ◽  
P. Gullberg ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Brain Lesions ◽  
Emission Tomography ◽  
Supratentorial Gliomas ◽  
Positron Emission ◽  
Number Of Patients ◽  
Methionine Uptake ◽  
Long Term Survivors

In previous studies of supratentorial gliomas with positron emission tomography (PET) and computed tomography (CT), high uptakes of L-methyl-11C-methionine (11C-L-methionine) were found even in astrocytomas without blood-brain barrier defects as judged by CT or 68Ga-EDTA PET. In a number of patients examined after radiation therapy, there were no consistent changes in the high uptake values. In the present investigation PET and CT were compared with regard to their abilities to visualize and delineate recurrent tumors and treatment-induced brain defects and to differentiate between them. The study was undertaken on four patients who were long-term survivors after treatment for high-grade gliomas. For PET, 11C-L-methionine and 68Ga-EDTA were used. In two patients recurrent/residual tumors appeared considerably larger with 11C-L-methionine PET than with CT or 68Ga-EDTA PET. In one patient, no signs of recurrence were seen with any of these three methods, and in a fourth patient, whose condition was clinically stable, the findings at PET with 11C-L-methionine were non-specific. In areas corresponding to the surgical parenchymal defects, the 11C-L-methionine uptake and, except in one case, the local blood volume was markedly reduced. PET with 11C-L-methionine thus has a potential for distinguishing between postoperative brain lesions and tumor recurrence with a higher accuracy than CT.

Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making

2008 ◽  
Vol 24 (02) ◽  
pp. 212-220 ◽  
Author(s):  
Raphaël Remonnay ◽  
Magali Morelle ◽  
Pascal Pommier ◽  
Francesco Giammarile ◽  
Marie-Odile Carrère
Keyword(s):  
Lung Cancer ◽  
Decision Making ◽  
Positron Emission Tomography ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Emission Tomography ◽  
Positron Emission ◽  
The Mean ◽  
Mean Cost ◽  
Radiotherapy Treatment

Objectives:Positron emission tomography (PET) is an innovative imaging tool. Associated with computed tomography (CT), it allows a better definition for the tumor volume for radiotherapy, compared with CT only. The aim of this study was to assess the effects of PET on resource allocation (costs and savings) and on the choice of the following treatment in radiotherapy.Methods:In 2004 and 2005, 209 patients were enrolled (97 patients with Hodgkin's disease and 112 with non-small cell lung cancer) in a national study conducted in eight hospitals. Two treatment decisions made on the basis of CT only or CT associated with PET, were compared in a prospective study where each subject was his/her own control. The direct medical cost of using PET was assessed by microcosting, using data collected from specific questionnaires. The costs of new tests and the costs and savings associated with changes in the chosen treatment were calculated on the basis of reimbursement rates.Results:The mean cost of using PET was approximately €800 per patient (50 percent for the radionuclide18F-FDG [2-[18F]fluoro-2-deoxy-D-glucose]). Radiotherapy treatments were modified for 10 percent of patients with Hodgkin's disease versus 40 percent of patients with lung cancer. Overall, the use of PET induced both increases and decreases in the mean cost per patient: the net effect was a €425 and €931 cost increase in lung cancer and Hodgkin's disease, respectively.Conclusions:The use of PET for radiotherapy decision making seems more valuable for lung cancer than for Hodgkin's disease, both in terms of costs and changes in radiotherapy treatment. This result might help policy makers for prioritization.

Sign in / Sign up

Export Citation Format

Share Document